Nogapendekin alfa inbakicept
- Generic Name
- Nogapendekin alfa inbakicept
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
- Conditions
- Non Hodgkin's Lymphoma Refractory/Relapsed
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05618925
- Locations
- 🇺🇸
Hoag Memorial Hospital, Newport Beach, California, United States
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
- Conditions
- Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05445882
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
- Conditions
- Colorectal CarcinomaColorectal NeoplasmLynch Syndrome
- Interventions
- Biological: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: ColonoscopyDrug: Placebo AdministrationOther: Questionnaire Administration
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 186
- Registration Number
- NCT05419011
- Locations
- 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 28
- Registration Number
- NCT05245292
- Locations
- 🇺🇸
Weill Cornell Medicine, Cornell Clinical Trials Unit, New York, New York, United States
🇺🇸The Rockefeller University, New York, New York, United States
🇺🇸Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania, United States
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
- Conditions
- Stage IIIC Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Recurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
- Interventions
- Dietary Supplement: CobalaminDietary Supplement: Folic Acid
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 82
- Registration Number
- NCT05096663
- Locations
- 🇺🇸
Kaiser Permanente West Los Angeles, Los Angeles, California, United States
🇺🇸Illinois CancerCare-Princeton, Princeton, Illinois, United States
🇺🇸UPMC-Mercy Hospital, Pittsburgh, Pennsylvania, United States
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
- Conditions
- Non-small Cell Lung CancerNSCLCNon-small Cell CarcinomaNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT05007769
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
- Conditions
- Gastroesophageal Junction (GEJ) CancersAdvanced HNSCC
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04847466
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Thai Red Cross AIDS Research Centre
- Target Recruit Count
- 14
- Registration Number
- NCT04505501
- Locations
- 🇹ðŸ‡
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
- Conditions
- Small Bowel CancersColorectal Cancers
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT04491955
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT04390399
- Locations
- 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
🇺🇸Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸Hoag memorial Presbyterian Hospital, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.